Abstract
Epidermal growth factor inhibition (EGFR) is emerging as an important treatment modality in several epithelial malignancies, including head and neck squamous cell carcinoma (HNSCC). Despite some notable successes, less than 20% of patients respond to EGFR inhibition due to intrinsic and acquired resistance. Since EGFR inhibition is already used for lung, colorectal, breast and pancreas cancers in addition to HNSCC, overcoming treatment resistance would have a major impact on outcome. When the mechanisms of intrinsic resistance are identified, including mutations in the EGFR receptor, alternative therapeutic approaches should be employed. Mechanisms of acquired resistance that may be amenable to pharmacological therapies include dysregulation of EGFR degradation, constitutive activation of overlapping signal transduction pathways, especially cMET/HER3, the PI3K/Akt resistance pathway, angiogenesis and epithelial to mesenchymal transition. COX-2 is another promising target for HNSCC and preclinical data suggest that COX-2 inhibitors can affect most of the described acquired EGFR resistance pathways. Several combined EGFR and COX-2 inhibition trials have been completed and demonstrate promise for HNSCC. Combinatorial strategies of combined inhibition of EGFR and acquired resistance pathways in combination with radiation or chemotherapy are warranted.
Keywords: EGFR, COX-2, head and neck cancer, erlotinib, celecoxib, radiation
Current Cancer Drug Targets
Title: Dual EGFR and COX-2 Inhibition as a Novel Approach to Targeting Head and Neck Squamous Cell Carcinoma
Volume: 9 Issue: 8
Author(s): J. Kao, A. T. Sikora and S. Fu
Affiliation:
Keywords: EGFR, COX-2, head and neck cancer, erlotinib, celecoxib, radiation
Abstract: Epidermal growth factor inhibition (EGFR) is emerging as an important treatment modality in several epithelial malignancies, including head and neck squamous cell carcinoma (HNSCC). Despite some notable successes, less than 20% of patients respond to EGFR inhibition due to intrinsic and acquired resistance. Since EGFR inhibition is already used for lung, colorectal, breast and pancreas cancers in addition to HNSCC, overcoming treatment resistance would have a major impact on outcome. When the mechanisms of intrinsic resistance are identified, including mutations in the EGFR receptor, alternative therapeutic approaches should be employed. Mechanisms of acquired resistance that may be amenable to pharmacological therapies include dysregulation of EGFR degradation, constitutive activation of overlapping signal transduction pathways, especially cMET/HER3, the PI3K/Akt resistance pathway, angiogenesis and epithelial to mesenchymal transition. COX-2 is another promising target for HNSCC and preclinical data suggest that COX-2 inhibitors can affect most of the described acquired EGFR resistance pathways. Several combined EGFR and COX-2 inhibition trials have been completed and demonstrate promise for HNSCC. Combinatorial strategies of combined inhibition of EGFR and acquired resistance pathways in combination with radiation or chemotherapy are warranted.
Export Options
About this article
Cite this article as:
Kao J., Sikora T. A. and Fu S., Dual EGFR and COX-2 Inhibition as a Novel Approach to Targeting Head and Neck Squamous Cell Carcinoma, Current Cancer Drug Targets 2009; 9 (8) . https://dx.doi.org/10.2174/156800909790192437
DOI https://dx.doi.org/10.2174/156800909790192437 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Telomerase Therapeutics for Degenerative Diseases
Current Molecular Medicine Pan-Amyloid Oligomer Specific scFv Antibody Attenuates Memory Deficits and Brain Amyloid Burden in Mice with Alzheimer’s Disease
Current Alzheimer Research Monitoring Kidney Function in Neuroendocrine Tumor Patients Treated with <sup>90</sup>Y-DOTATOC: Associations with Risk Factors
Current Radiopharmaceuticals Novel Therapeutic Approaches in Pancreatic Cancer Based on Genomic Alterations
Current Pharmaceutical Design Aliphatic and Aromatic Oxidations, Epoxidation and S-Oxidation of Prodrugs that Yield Active Drug Metabolites
Current Medicinal Chemistry Connection between JAK/STAT and PPARγ Signaling During the Progression of Multiple Sclerosis: Insights into the Modulation of T-Cells and Immune Responses in the Brain
Current Molecular Pharmacology Structure Activity Relationship Studies of Gymnemic Acid Analogues for Antidiabetic Activity Targeting PPARγ
Current Computer-Aided Drug Design Overview of Prostate Biomarkers as Potential Targets for Immunotherapy
Current Cancer Therapy Reviews The High Mobility Group A1 (HMGA1) Transcriptome in Cancer and Development
Current Molecular Medicine Applications of Gene Therapy to the Treatment of Chronic Pain
Current Gene Therapy IL-2 Receptor Targeted Immunomodulatory Biologics: The Past, Present, and Future
Current Immunology Reviews (Discontinued) Genetically Engineered Stem Cells for Therapeutic Gene Delivery
Current Gene Therapy Novel Target Identification Technologies for the Personalised Therapy of Type II Diabetes and Obesity
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Implications of Palmitoleic Acid (Palmitoleate) On Glucose Homeostasis, Insulin Resistance and Diabetes
Current Drug Targets Natural Products and their Analogues as Efficient Anticancer Drugs
Mini-Reviews in Medicinal Chemistry FOXO and FOXM1 in Cancer: The FOXO-FOXM1 Axis Shapes the Outcome of Cancer Chemotherapy
Current Drug Targets A Targeted Therapy for Protein and Lipid Kinases in Chronic Lymphocytic Leukemia
Current Medicinal Chemistry Synthesis and Preliminary Evaluation of 5-[18F]fluoroleucine
Current Radiopharmaceuticals Antitumor and Antiviral Activity of Pentacyclic Triterpenes
Mini-Reviews in Organic Chemistry Follow the ATP: Tumor Energy Production: A Perspective
Anti-Cancer Agents in Medicinal Chemistry